Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00503880 · ClinicalTrials.gov registry record · Phase 1
Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes
A Phase 1 study, sponsored by University of Nebraska.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00503880 is a Phase 1 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 2 participants.
The verdict
NCT00503880, a Phase 1 study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as G-CSF, may increase the number of immune cells found in bone marrow or in peripheral blood and may help the immune system recover from the side effects of chemotherapy. Giving clofarabine and cytarabine together with G-CSF may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of clofarabine and to see how well it works when given together with cytarabine and G-CSF in treating patients with myelodysplastic syndromes.
Interventions
- GENETIC microarray analysis
- PROCEDURE biopsy
- DRUG clofarabine
- BIOLOGICAL filgrastim
- DRUG cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2007-05-07 |
| Est. Completion | 2009-10-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00503880
The ClinicalTrials.gov registry entry for NCT00503880 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which microarray analysis is the first listed.
NCT00503880 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00503880 about?
NCT00503880 is a clinical study titled "Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes". RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as G-CSF, may increase the number of immune cells found in bone marrow...
What is the current status of trial NCT00503880?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2007-05-07. Estimated completion is 2009-10-13.
What interventions are being tested in trial NCT00503880?
The interventions under investigation include: microarray analysis (GENETIC), biopsy (PROCEDURE), clofarabine (DRUG), filgrastim (BIOLOGICAL), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00503880?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.